Alan Dursun: Global Training in Kuala Lumpur Advancing Advocacy and Patient Impact
Alan Dursun, Senior Case Manager at Allianz Australia, shared a post on LinkedIn:
“Day 2 in Kuala Lumpur, and Day 1 of the Global National Member Organization Training, was a really valuable and thought provoking day.
The plenary sessions set the tone well, especially Dr Glenn Pierce’s presentation on the evolving treatment landscape.
It was incredibly insightful to hear about how treatment continues to progress, from current therapies through to emerging options, and what that means for patient communities, education, access, and future advocacy.
Sessions like that are a strong reminder that while science is advancing quickly, the work of patient organisations remains just as important in helping ensure those advances translate into real and equitable outcomes for people living with bleeding disorders.
Another strong theme throughout the day was advocacy.
From the strategic advocacy plenary through to the breakout workshops, the focus was not just on understanding issues, but on how to respond to them in a practical and effective way.
In our group, facilitated by Ekawat Suwantaroj, we worked through project scenarios, SWOT analysis, stakeholder thinking, and message building.
That made the learning feel very real and grounded, especially when applying it to challenges that patient organisations may face in their own countries.
One of my biggest takeaways from today was that effective advocacy is not just about passion.
It is about being clear on the issue, understanding the barriers, knowing your audience, and building a practical path forward that can actually create change.
Grateful to be here learning alongside passionate leaders from around the world, and proud to represent Australia in these important conversations.
Looking forward to the next few days.”
Stay uodated with Hemostasis Today.
-
Aug 12, 2026, 10:58Raed Ahmed: New Insights into Severe Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
-
Aug 12, 2026, 10:27Cliff Oguk: Designing Health AI Around Real-World Clinical Needs
-
Aug 12, 2026, 09:51Orlando Agrippa: Why Promising Sickle Cell Therapies Continue to Fall Short
-
Aug 12, 2026, 09:34Tiffany Hall: Why Hemoglobin Alone Is Not Enough Before Cardiac Surgery
-
Aug 12, 2026, 08:33Craig Clapper: What the Andrea Doria Collision Teaches Us About Safety
-
Aug 12, 2026, 08:16Chengyong Yang: Can Plasma Reveal Cell Specific Signals
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?